scholarly journals CD44 Variant Exon 6 Isoform Expression as a Potential Predictor of Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Primariadewi Rustamadji ◽  
Elvan Wiyarta ◽  
Kristina A. Bethania
Keyword(s):  
Breast Carcinoma ◽  
Univariate Analysis ◽  
Tumor Grade ◽  
Invasive Breast Carcinoma ◽  
Cross Sectional ◽  
Primary Tumors ◽  
Variant Exon ◽  
Cd44 Variant ◽  
Regional Metastases ◽  
Cd44v6 Expression

Background. Invasive breast carcinoma of no special type (IBC-NST) is the most widespread invasive carcinoma subtype causing primarily regional metastases of the lymphatic node (LNM). The capacity of CD44 variant exon 6 (CD44v6) expression as an LNM predictor biomarker in IBC-NST was explored. Methods. We conducted a cross-sectional research with 48 paraffin blocks containing IBC-NST primary tumors that were divided into two groups by LNM. The assessment has been carried out in terms of age, tumor size, tumor grade, lymphovascular invasion (LVI), and CD44v6 expression. The expression of CD44v6 was analyzed on the grounds of immunohistochemical (IHC) staining, while other data were taken from archives. Statistical analysis is carried out by univariate, multivariate, and AUROC. Results. CD44v6 exhibits a dominant expression in IBC-NST tumor cells. Univariate analysis revealed a significant association between CD44v6 and LNM status ( p = 0.001 ). Multiple logistic regression results showed that CD44v6 expression and LVI were significantly associated with LNM with OR 10.7 (95% CI: 2.43 to 47.08) and 6.22 (95% CI: 1.4 to 27.88), respectively. CD44v6 expression was able to discriminate against LNM with AUROC 0.863 ± 0.053 (95% CI: 0.759 to 0.967) at the H-score cut-off 133.889 (75% sensitivity and 83.3% specificity). Conclusion. CD44v6 expression and LVI are potential predictors of LNM in IBC-NST. The H-score cut-off of the CD44v6 expression can also be used as a threshold for classification in further investigation.

Progesterone and estrogen receptors in meningiomas: prognostic considerations

1997 ◽  
Vol 86 (1) ◽  
pp. 113-120 ◽  
Author(s):  
Dora W. Hsu ◽  
Jimmy T. Efird ◽  
E. Tessa Hedley-Whyte
Keyword(s):  
Mitotic Index ◽  
Hormone Receptors ◽  
Univariate Analysis ◽  
Inverse Correlation ◽  
Tumor Grade ◽  
Steroid Hormone Receptors ◽  
Nuclear Staining ◽  
Primary Tumors ◽  
Content Type ◽  
The Mean

✓ Meningiomas often contain steroid hormone receptors, but the correlation of receptor presence with patient outcome or mitotic index is unclear. Intracranial meningiomas from 70 patients (27 males and 43 females, mean age 52.9 + 1.7 years [mean ± standard error of the mean], range 15–78 years) were evaluated immunocytochemically for female sex hormone receptors using specific monoclonal antibodies. Prognostic correlations were determined using statistical analyses that included clinical and histological variables. Twenty-eight tumors were benign, 27 had atypical features, and 15 were malignant. Thirty tumors were meningotheliomatous, 11 were fibroblastic, 28 were transitional, and one was secretory. Twenty-nine of the 70 primary tumors recurred (mean interval to recurrence 50.1 ± 10 months). The mean progression-free follow-up period for patients without recurrence was 82.1 ± 7.7 months. Nuclear staining for the progesterone receptor (PR) was found in 58 cases (83%) and PR status was scored as 0 (0% nuclei positive), 1 (< 1%), 2 (1–9%), 3 (10–49%), or 4 (> 50%). Only six tumors (8.6%) contained nuclear estrogen receptor (ER) staining, which was limited to a small number of nuclei (< 1%). Fisher's exact test (two-tailed) showed an inverse correlation between tumor grade and PR staining score (p ≤ 0.001), with 96% of benign and 40% of malignant meningiomas containing PR-positive nuclei. No correlation between age or histological subtype and PR score was detected. Meningiomas from female patients had more PRs (p ≤ 0.05). Analysis of variance revealed that the mitotic index (total counts of mitoses per 10 high-power fields) for tumors with 0 PR staining (18 ± 4.4) was higher (p ± 0.0001) than for those with PR scores of 1 to 4 (4.3 ± 1.9, 5.1 ± 2, 2.2 ± 0.8, and 1.7 ± 0.9, respectively). Univariate analysis indicated that the absence of PR, high mitotic index, and higher tumor grade were significant factors for shorter disease-free intervals. Multivariate analysis showed that a three-factor interaction model, with a PR score of 0, mitotic index greater than 6, and malignant tumor grade, was a highly significant predictor (p ≤ 0.0001) for worse outcome in patients harboring meningiomas. These data indicate that the presence of PRs, even in a small number of tumor cells, is a favorable prognostic factor for meningiomas.

scholarly journals Expression of Survivin in Basal-Like and Triple Negative Breast Carcinoma and Associations with Clinicopathological Parameters

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Madatang A. ◽  
Mohd Nafi S.N. ◽  
Jaafar H. ◽  
Wan Abdul Rahman W.F.
Keyword(s):  
Breast Carcinoma ◽  
Triple Negative ◽  
Molecular Subtype ◽  
Survivin Expression ◽  
Prognostic Indicator ◽  
Invasive Breast Carcinoma ◽  
Clinicopathological Parameters ◽  
Tubule Formation ◽  
Cross Sectional ◽  
Triple Negative Breast Carcinoma

INTRODUCTION: Triple negative breast carcinoma (TNBC) molecular subtype and its variant; basal-like triple negative (BLTN) carcinoma is an established poor prognostic indicator. The aim of this study is to analyse the survivin expression in TNBC and BLTN, and relating the results with clinicopathological parameters. MATERIALS AND METHODS: We conducted a cross sectional study using 94 archived formalin-fixed paraffin embedded tissue blocks of invasive breast carcinoma, no special type (NST). Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (HER2) were used as surrogate markers to classify the cases into molecular subtypes. Samples with triple negative phenotype (ER, PR and HER2 negative) were stained with CK 5/6 to identify the BLTN subtype. All the samples were also immunostained for survivin. RESULT: Out of 94 cases, 41.5% (39 cases) were TNBC. Among the TNBC cases, only 41.0% (16 cases) were BLTN subtype when they found to be positive for CK 5/6. Among 94 cases of invasive breast carcinoma, 28.7% (27 cases) were survivin positive with (53.8%) 21 cases were TNBC and (11%) 6 cases were non-TNBC (p< 0.001). Among 16 cases of BLTN subtype, only 8 cases were survivin positive (p = 0.752). Survivin expression was also statistically significant with tubule formation (p=0.029), nuclear pleomorphism (p=0.008), tumour grade (p=0.010), ER status (p< 0.001) and PR status (p=0.001). CONCLUSION: Survivin expression was statistically significant in invasive breast carcinoma. Even though the expression was significantly high in TNBC, it is not related to whether it is a basal-like or non-basal-like variant.

SGK1 regulated apoptosis in invasive breast carcinoma.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e13061-e13061
Author(s):  
Yuxin Song ◽  
Lei Li ◽  
YinJiao Fei ◽  
Wenquan Chen ◽  
Guan qun Wo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Breast Carcinoma ◽  
Western Blot ◽  
Univariate Analysis ◽  
Stage Iv ◽  
Invasive Breast Carcinoma ◽  
Gene Set Enrichment Analysis ◽  
Pcr Assay ◽  
Qrt Pcr

e13061 Background: Worldwide, breast cancer is the most common type of cancers and the presentation of drug resistance is often associated with poor prognosis. Previous studies have shown the mechanism of drug resistance was affected by apoptosis at different levels in the signaling cascades. This article is aimed to explore the relationship between the serum and glucocorticoid-regulated kinase 1 (SGK1) and apoptosis in invasive breast cancer (IBC). Methods: We evaluated the expression of SGK1 in IBC using publicly available data from The Cancer Genome Atlas (TCGA) and Curtis Breast program. TaqMan probe-based qRT-PCR assay and Western Blot analysis were performed to quantitatively detect the expression of SGK1 at RNA and protein levels in the IBC specimens. Clinicopathologic characteristics associated with overall survival were tested by Cox regression. Gene Set Enrichment Analysis (GSEA) was performed to mine the biological pathways involved in IBC pathogenesis related SGK1 regulatory network using MSigDB database. Immunohistochemistry staining (IHC) was used to detect apoptotic markers Fas, Bcl2 and SGK1 in the IBC specimens. Results: Totally 1109 IBC samples with SGK1 expression data were downloaded from TCGA databases for analyzed. SGK1 expression was elevated in normal breast tissues compared with both invasive ductal carcinoma and invasive lobular carcinoma (p < 0.0001). Among them, SKG expression in 112 tumor tissues was significantly lower than that in paracancerous tissues, especially in advanced patients with TNM stage IV. Western Blot and qRT-PCR assay confirmed that SGK1 expression in IBC was distinctly lower than normal. The Kaplan-Meier survival analysis showed that decreased expression of SGK1 was significantly correlated with the clinical stage (p = 0.036). In Curtis Breast program, we further verified SGK1 gene expression was reduced in stage IV than stage I. The univariate analysis demonstrated that clinicopathologic variables associated with poor survival include age, advanced stage, lymph nodes, distant metastasis and deep myometrial invasion. GSEA revealed that apoptosis was differentially enriched when SGK1 was highly expressed. Similarly, TCGA data indicated that the positive rate of SGK1 was higher in Fas positive IBCs, and the same result was also obtained by IHC in the IBC specimens. Conclusions: Expression of SGK1 regulated apoptosis in invasive breast carcinoma, which might be a potential therapeutic target to overcome refractory and drug-resistant breast cancer.

Agreement between MRI and pathologic analyses for determination of tumor size and correlation with immunohistochemical factors of invasive breast carcinoma

2017 ◽  
Vol 59 (1) ◽  
pp. 50-57 ◽  
Author(s):  
Eun Young Yoo ◽  
Sang Yu Nam ◽  
Hye-Young Choi ◽  
Min Ji Hong
Keyword(s):  
Breast Carcinoma ◽  
Tumor Size ◽  
Molecular Subtype ◽  
Univariate Analysis ◽  
Growth Factor Receptor ◽  
Invasive Breast Carcinoma ◽  
Breast Carcinomas ◽  
Luminal A ◽  
Luminal B ◽  
Invasive Breast Carcinomas

Background There may be discordance between tumor size determined by magnetic resonance imaging (MRI) and that observed during pathologic analyses. Purpose To evaluate MRI-pathology concordance of tumor size in patients with invasive breast carcinoma. Material and Methods Data from 307 invasive breast carcinomas were analyzed retrospectively. Preoperative breast MRI was reviewed for size, lesion type, morphology, and dynamic contrast-enhanced tumor kinetics. MRI tumor size was compared with tumor size measurements from the pathologic analysis. Concordance was defined as a difference in diameter of ≤ 0.5 cm. MRI-pathology concordance was compared according to clinical and histopathologic features. Results The mean tumor size on MRI was 2.48 ± 1.41 cm. Tumor measurements determined by MRI were not significantly different from those recorded in the pathologic reports (2.56 ± 1.61 cm, P = 0.199). MRI-pathology concordance was found in 229/307 (74.6%) cases; the size was overestimated in 36 (11.7%) tumors and underestimated in 42 (13.7%). On univariate analysis, MRI-pathology discordance was associated with larger tumor size ( P < 0.001), estrogen receptor (ER) negativity ( P = 0.006), and lymphovascular invasion ( P = 0.003). Human epidermal growth factor receptor 2 positive molecular subtype showed worse correlation between the tumor size measured by MRI and pathology compared with luminal A and luminal B subtypes ( P = 0.008 and 0.007). On multivariate analysis, tumor size and ER status significantly influenced MRI-pathology concordance ( P < 0.05). Conclusion ER negativity and larger tumor size were strongly associated with MRI-pathology discordance in invasive breast carcinomas. Awareness of these factors might improve surgical planning.

scholarly journals Correlation of CD133 and SOX2 Expression with Regional Lymph Nodes Metastatic Status in Invasive Breast Carcinoma of No Special Type

2021 ◽  
Vol 15 (1) ◽  
pp. 4
Author(s):  
Dyah Fauziah ◽  
Sutrisno Sutrisno ◽  
Gondo Mastutik
Keyword(s):  
Breast Carcinoma ◽  
Lymph Nodes ◽  
Invasive Breast Carcinoma ◽  
High Expression ◽  
Regional Lymph Nodes ◽  
Cross Sectional ◽  
Cd133 Expression ◽  
Sox2 Expression ◽  
Significant Difference ◽  
Cross Sectional Design

Background: CD133 overexpression can increase cell proliferation, migration, and epithelialmesenchymal transition that promotes metastasis. CD133 expression is induced by hypoxiainduced factor (HIF) which requires SOX2 binding in the promoter region. SOX2 is an embryonal transcription factor that plays a role in the development of malignancy. The study aimed to analyze the expression of CD133 and SOX2 with regional lymph nodes (LN) metastatic status in invasive breast carcinoma of no special type (NST). Methods: The study was a cross-sectional design. Forty-five samples were retrieved from pathology archives in Dr. Soetomo Hospital from January to December 2018. Samples were divided into 2 groups, with and without regional LN metastasis. Immunohistochemistry with CD133 and SOX2 was applied to all samples. CD133 expression was assessed by immunoreactive score, and SOX2 expression was assessed by the percentage of tumor positive cells.Results: There was no significant difference in CD 133 expression between invasive breast carcinoma of NST with and without regional LN metastases (P = .990). A positive correlation was found in SOX2 expression between breast carcinoma with and without regional LN metastasis (P = .000; rs = .518). There was no correlation between CD133 and SOX2 expression (P = .082), which means that the high expression of CD133 did not affect SOX2 expression.Conclusions: CD133 expression was not significantly different in breast carcinoma with and without LN metastasis. The high expression of SOX2 was found significantly correlated with regional LN metastasis. SOX2 expression may become a potential prognostic marker in invasive breast carcinoma of NST. regional LN metastasis

scholarly journals Immunohistochemical Study of Androgen Receptor Expression in Estrogen Receptor-Negative Invasive Breast Carcinoma and its Relation with Clinicopathologic Factors

2020 ◽  
Vol 8 (A) ◽  
pp. 615-622
Author(s):  
Shereen E. Abdelaal ◽  
Samia M. Gabal ◽  
Amina A. Gamal el Din ◽  
Hala N. Hosni ◽  
Hafiza A. Sharaf
Keyword(s):  
Estrogen Receptor ◽  
Lymph Node ◽  
Androgen Receptor ◽  
Breast Carcinoma ◽  
Triple Negative ◽  
Tumor Grade ◽  
Invasive Breast Carcinoma ◽  
Lymph Node Status ◽  
Breast Carcinomas ◽  
Clinicopathologic Factors

BACKGROUND: Estrogen receptor (ER)-negative breast carcinomas lack the expression of ER and they have no targeted hormone therapies. The androgen receptor (AR) is a newly emerge biomarker. Detecting AR in these tumors may provide a target for future therapies. AIM: The aim of the study is to examine the immunohistochemical expression profiles of AR protein in ER-negative invasive breast carcinomas and to assess the relation between AR expression and the clinicopathologic factors such as age, tumor size, tumor grade, tumor type, immunohistochemical type, lymph node status, and Ki67 expression. METHODS: Sixty paraffin blocks of ER-negative invasive breast carcinoma cases were stained immunohistochemically by AR. Positive expression was defined as ≥1% nuclear staining. RESULTS: AR positivity was detected in 55% of the studied cases. The positive cases were scored by H-score with a median=117, and a range of 3–285 and by Allred score with a median=7, and a range of 3-8. AR is expressed in 60.9% of triple-negative breast carcinoma cases. AR expression was higher in older age, and there were significant positive correlations between the degree of AR expression (AR%, AR intensity, and H-score) and age (p=0.050, 0.007, 0.033, respectively). There was non-significant negative correlation between Ki67% and the degree of AR expression (AR%, AR intensity, H-score, and Allred score). Regarding different histological types, tumor grade, tumor size, lymph node status, and immunohistochemical types, there was no significant difference between AR positive and AR negative cases. CONCLUSION: AR is frequently expressed in ER-negative invasive breast carcinoma; especially in older age, and in a large number of triple-negative subtypes. This may give chance to benefit from future AR target therapy. We recommend further research work on AR expression in the special histologic subtypes of ER-negative breast carcinoma and in the triple negative group.

Expression of CD44 variant exon epitopes in noninvasive breast carcinoma

1995 ◽  
Vol 121 (S1) ◽  
pp. A40-A40
Author(s):  
H. P. Sinn ◽  
P. Dallt ◽  
K. H. Heidert ◽  
M. Kaufmann
Keyword(s):  
Breast Carcinoma ◽  
Variant Exon ◽  
Cd44 Variant

scholarly journals Correlation of cyclin D1 between hormones receptors and other clinical parameters in invasive breast carcinoma

2020 ◽  
Vol 8 (12) ◽  
pp. 4436
Author(s):  
Seema Singh ◽  
Abdul Mabood ◽  
Neetu Dwivedi ◽  
M. Qamar Alam ◽  
Abhinav Gangwar
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Lymph Node Metastasis ◽  
Cyclin D1 ◽  
Uttar Pradesh ◽  
Invasive Breast Carcinoma ◽  
Tumour Grade ◽  
Observation Study ◽  
Cross Sectional ◽  
Node Metastasis

Background: Breast carcinoma is the most common malignancy in women. The prognosis of breast carcinoma is determined by different prognostic factors including age of patients, type of tumour, stage of tumours, grade of tumors, presence or absence of metastasis and hormones receptor status. The present study was conducted to assess the expression of cyclin D1 in invasive breast carcinoma and its correlation with age, tumour grade, lymph node metastasis and hormones receptors (estrogen receptors and progesterone receptors).Methods: Present study was conducted in department of pathology UPUMS, Saifai, Etawah, Uttar Pradesh. This was a prospective cross sectional observation study conducted on 21 mastectomy specimen from January 2019 to June 2021, diagnosed as invasive breast carcinoma on routine haematoxylin and eosin stain. Immunohistochemistery marker was scored by using allred scoring methods. Grading was calculated according to Nottingham grading system.Results: It was observed out of 21 cases 9 (42.8%) cases were showing cyclin D1 positivity. In our study 14 cases were estrogen receptor and progesterone receptor positive, out of 14 ER and PR positive cases 9 (64.2%) cases showing cyclin D1 positivity. There was significant correlation between cyclin D1 and hormones receptors (ER and PR). No significant correlation between cyclin D1and age, tumour grade and lymph node metastasis.Conclusions: Present study depicts significant correlation between cyclin D1 and hormones receptors (ER and PR). No significant correlation between cyclin D1and age, tumour grade and lymph node metastasis.

Sign in / Sign up

Export Citation Format

Share Document